ChemistryRX

Message from Sponsor

Hi, everyone!

We would like to highlight the recent case report on the successful use of compounded 1% trametinib cream for epidermal and sebaceous nevi in a 20-month-old child with a somatic KRAS mutation (Haller et al., Pediatric Dermatology 2024). Topical 1% trametinib led to reduced pruritus, and lightening and thinning of the nevi.

Trametinib cream for skin conditions related to aberrant MAP signaling is coverable by insurances, and we are happy to help with letters of medical necessity and prior authorization requests, as always. Please let me know any time if you have questions.

Thanks so much,

Lars

ChemistryRx